Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Down 48.9% in May

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 225,674 shares, a decrease of 48.9% from the May 14th total of 441,245 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 279,716 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in SHPH. Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 3rd quarter worth $357,000. Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter worth about $124,000. Boothbay Fund Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter worth about $37,000. Finally, Geode Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth about $26,000. 4.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Down 6.5%

Shares of NASDAQ:SHPH opened at $3.91 on Friday. Shuttle Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $55.90. The stock has a market capitalization of $2.50 million, a P/E ratio of -0.82 and a beta of 0.18. The firm has a fifty day simple moving average of $7.12 and a two-hundred day simple moving average of $11.87.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .